KR101421852B1 - 카세인 키나제 억제제로서의 이미다졸 유도체 - Google Patents
카세인 키나제 억제제로서의 이미다졸 유도체 Download PDFInfo
- Publication number
- KR101421852B1 KR101421852B1 KR1020127013537A KR20127013537A KR101421852B1 KR 101421852 B1 KR101421852 B1 KR 101421852B1 KR 1020127013537 A KR1020127013537 A KR 1020127013537A KR 20127013537 A KR20127013537 A KR 20127013537A KR 101421852 B1 KR101421852 B1 KR 101421852B1
- Authority
- KR
- South Korea
- Prior art keywords
- imidazol
- alkyl
- pyrimidin
- amine
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25550609P | 2009-10-28 | 2009-10-28 | |
| US61/255,506 | 2009-10-28 | ||
| PCT/IB2010/054749 WO2011051858A1 (en) | 2009-10-28 | 2010-10-20 | Imidazole derivatives as casein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20120088759A KR20120088759A (ko) | 2012-08-08 |
| KR101421852B1 true KR101421852B1 (ko) | 2014-07-22 |
Family
ID=43301770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127013537A Expired - Fee Related KR101421852B1 (ko) | 2009-10-28 | 2010-10-20 | 카세인 키나제 억제제로서의 이미다졸 유도체 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8518944B2 (enExample) |
| EP (1) | EP2493876B1 (enExample) |
| JP (1) | JP5784620B2 (enExample) |
| KR (1) | KR101421852B1 (enExample) |
| CN (1) | CN102686580B (enExample) |
| AR (1) | AR078797A1 (enExample) |
| AU (1) | AU2010311035B2 (enExample) |
| CA (1) | CA2777632C (enExample) |
| DK (1) | DK2493876T3 (enExample) |
| ES (1) | ES2460065T3 (enExample) |
| HR (1) | HRP20140252T1 (enExample) |
| IL (1) | IL219190A0 (enExample) |
| IN (1) | IN2012DN03182A (enExample) |
| MX (1) | MX2012004997A (enExample) |
| PL (1) | PL2493876T3 (enExample) |
| PT (1) | PT2493876E (enExample) |
| RS (1) | RS53246B (enExample) |
| SI (1) | SI2493876T1 (enExample) |
| TW (1) | TW201125864A (enExample) |
| UY (1) | UY32977A (enExample) |
| WO (1) | WO2011051858A1 (enExample) |
| ZA (1) | ZA201202776B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008076556A2 (en) | 2006-11-15 | 2008-06-26 | Massachusetts Eye & Ear Infirmary | Generation of inner ear cells |
| EP3181133B1 (en) | 2010-12-20 | 2019-07-24 | Pfizer Inc | Novel fused pyridine compounds as casein kinase inhibitors |
| EP2892506B1 (en) | 2012-09-07 | 2021-11-03 | Massachusetts Eye & Ear Infirmary | Treating hearing loss with the gamma-secretase inhibitor ly411575 |
| JP6267231B2 (ja) | 2012-12-21 | 2018-01-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール |
| US9732065B2 (en) | 2013-05-30 | 2017-08-15 | Sumitomo Dainippon Pharma Co., Ltd. | Cyclic aminomethyl pyrimidine derivative |
| SG11201606427SA (en) | 2014-02-07 | 2016-09-29 | Agency Science Tech & Res | 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis |
| WO2016022776A2 (en) | 2014-08-06 | 2016-02-11 | Massachusetts Eye And Ear Infirmary | Increasing atoh1 life to drive sensorineural hair cell differentiantion |
| WO2016149756A1 (en) | 2015-03-23 | 2016-09-29 | The University Of Melbourne | Treatment of respiratory diseases |
| WO2017096233A1 (en) | 2015-12-04 | 2017-06-08 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss by inhibition of casein kinase 1 |
| CN109219439B (zh) | 2016-01-29 | 2022-09-20 | 马萨诸塞眼科耳科诊所 | 内耳支持细胞的扩增和分化及其使用方法 |
| AU2018262108A1 (en) * | 2017-05-03 | 2019-11-21 | The University Of Melbourne | Compounds for the treatment of respiratory diseases |
| US10973820B2 (en) | 2017-12-13 | 2021-04-13 | Facio Intellectual Property B.V. | Compounds for treatment of diseases related to DUX4 expression |
| AU2019336540B2 (en) * | 2018-09-09 | 2025-02-13 | Qanatpharma Ag | Use of casein kinase 1 inhibitors for treating vascular diseases |
| AU2019374731B2 (en) * | 2018-11-07 | 2025-08-21 | Tianli Biotech Pty Ltd | Compounds and compositions for the treatment of respiratory diseases |
| TW202112368A (zh) | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
| CN115335057A (zh) * | 2020-03-27 | 2022-11-11 | 北京原基华毅生物科技有限公司 | 抑制酪蛋白激酶的方法 |
| EP4126878A4 (en) * | 2020-03-27 | 2024-07-10 | Gritscience Biopharmaceuticals Co., Ltd. | COMPOUNDS AS CASEIN KINASE INHIBITORS |
| AR122711A1 (es) * | 2020-06-25 | 2022-09-28 | Alchemedicine Inc | COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995002591A1 (en) | 1993-07-16 | 1995-01-26 | Smithkline Beecham Corporation | Tri-substituted imidazoles having multiple therapeutic properties |
| US6096739A (en) | 1996-03-25 | 2000-08-01 | Smithkline Beecham Corporation | Treatment for CNS injuries |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992012154A1 (en) * | 1990-12-31 | 1992-07-23 | Fujisawa Pharmaceutical Co., Ltd. | Imidazotriazine derivatives |
| US6239279B1 (en) | 1998-12-16 | 2001-05-29 | Smithkline Beecham Corporation | Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives |
| GB0108770D0 (en) * | 2001-04-06 | 2001-05-30 | Eisai London Res Lab Ltd | Inhibitors |
| JP2004536597A (ja) * | 2001-06-18 | 2004-12-09 | ザ ロックフェラー ユニバーシティー | 代謝共役型グルタミン酸受容体シグナル伝達経路を介する神経機能の調節 |
| CN100439367C (zh) * | 2003-12-11 | 2008-12-03 | 安万特药物公司 | 作为酪蛋白激酶Iε抑制剂的取代的1H-吡咯并[3,2-b、3,2-c和2,3-c]吡啶-2-甲酰胺以及相关类似物 |
| JO2629B1 (en) * | 2004-08-19 | 2012-06-24 | افينتيس فارما سوتيكالز انك | Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon |
| ES2334927T3 (es) * | 2004-08-19 | 2010-03-17 | Aventis Pharmaceuticals Inc. | Derivados de 3-ariltioindol-2-carboxamida y sus analogos como imhibidores de caseina quinasa i. |
| CA2626789A1 (en) * | 2005-10-21 | 2007-04-26 | Exelixis, Inc. | Pyrimidinones as casein kinase ii (ck2) modulators |
| EP2308866A1 (de) * | 2009-10-09 | 2011-04-13 | Bayer CropScience AG | Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide |
| EP3181133B1 (en) * | 2010-12-20 | 2019-07-24 | Pfizer Inc | Novel fused pyridine compounds as casein kinase inhibitors |
-
2010
- 2010-10-20 MX MX2012004997A patent/MX2012004997A/es active IP Right Grant
- 2010-10-20 HR HRP20140252AT patent/HRP20140252T1/hr unknown
- 2010-10-20 RS RS20140157A patent/RS53246B/sr unknown
- 2010-10-20 ES ES10774282.7T patent/ES2460065T3/es active Active
- 2010-10-20 DK DK10774282.7T patent/DK2493876T3/en active
- 2010-10-20 KR KR1020127013537A patent/KR101421852B1/ko not_active Expired - Fee Related
- 2010-10-20 IN IN3182DEN2012 patent/IN2012DN03182A/en unknown
- 2010-10-20 EP EP10774282.7A patent/EP2493876B1/en active Active
- 2010-10-20 AU AU2010311035A patent/AU2010311035B2/en not_active Ceased
- 2010-10-20 WO PCT/IB2010/054749 patent/WO2011051858A1/en not_active Ceased
- 2010-10-20 PT PT107742827T patent/PT2493876E/pt unknown
- 2010-10-20 CA CA2777632A patent/CA2777632C/en not_active Expired - Fee Related
- 2010-10-20 CN CN201080059759.7A patent/CN102686580B/zh not_active Expired - Fee Related
- 2010-10-20 JP JP2012535977A patent/JP5784620B2/ja active Active
- 2010-10-20 PL PL10774282T patent/PL2493876T3/pl unknown
- 2010-10-20 SI SI201030539T patent/SI2493876T1/sl unknown
- 2010-10-25 US US12/911,030 patent/US8518944B2/en active Active
- 2010-10-25 TW TW099136328A patent/TW201125864A/zh unknown
- 2010-10-27 UY UY0001032977A patent/UY32977A/es not_active Application Discontinuation
- 2010-10-28 AR ARP100103948A patent/AR078797A1/es not_active Application Discontinuation
-
2012
- 2012-04-15 IL IL219190A patent/IL219190A0/en unknown
- 2012-04-16 ZA ZA2012/02776A patent/ZA201202776B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995002591A1 (en) | 1993-07-16 | 1995-01-26 | Smithkline Beecham Corporation | Tri-substituted imidazoles having multiple therapeutic properties |
| US6096739A (en) | 1996-03-25 | 2000-08-01 | Smithkline Beecham Corporation | Treatment for CNS injuries |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2493876A1 (en) | 2012-09-05 |
| JP2013509392A (ja) | 2013-03-14 |
| IL219190A0 (en) | 2012-06-28 |
| US8518944B2 (en) | 2013-08-27 |
| AU2010311035B2 (en) | 2013-05-16 |
| TW201125864A (en) | 2011-08-01 |
| PT2493876E (pt) | 2014-03-20 |
| HRP20140252T1 (hr) | 2014-04-25 |
| US20110098272A1 (en) | 2011-04-28 |
| WO2011051858A1 (en) | 2011-05-05 |
| MX2012004997A (es) | 2012-06-12 |
| SI2493876T1 (sl) | 2014-04-30 |
| ES2460065T3 (es) | 2014-05-13 |
| JP5784620B2 (ja) | 2015-09-24 |
| HK1171220A1 (en) | 2013-03-22 |
| AR078797A1 (es) | 2011-12-07 |
| PL2493876T3 (pl) | 2014-06-30 |
| AU2010311035A1 (en) | 2012-05-03 |
| UY32977A (es) | 2011-05-31 |
| CN102686580A (zh) | 2012-09-19 |
| EP2493876B1 (en) | 2014-02-12 |
| CA2777632C (en) | 2014-02-25 |
| CA2777632A1 (en) | 2011-05-05 |
| CN102686580B (zh) | 2014-09-10 |
| KR20120088759A (ko) | 2012-08-08 |
| ZA201202776B (en) | 2013-06-26 |
| DK2493876T3 (en) | 2014-03-10 |
| IN2012DN03182A (enExample) | 2015-09-25 |
| RS53246B (sr) | 2014-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5784620B2 (ja) | カゼインキナーゼ阻害剤としてのイミダゾール誘導体 | |
| EP3181133B1 (en) | Novel fused pyridine compounds as casein kinase inhibitors | |
| AU2018285131B2 (en) | Heteroaromatic compounds as Vanin inhibitors | |
| US8933095B2 (en) | KAT II inhibitors | |
| US20120053165A1 (en) | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators | |
| KR20150027267A (ko) | LRRK2 억제제로서의 4-(치환된-아미노)-7H-피롤로[2,3-d]피리미딘 | |
| MX2012013127A (es) | Compuestos heteroariloxiheterociclilo como inhibidores pde10. | |
| US20110224231A1 (en) | Novel Lactams as Beta Secretase Inhibitors | |
| US20120202787A1 (en) | Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators | |
| JP2017122103A (ja) | うつ病、糖尿病及びパーキンソン病のような幾つかの障害の処置において使用するためのｔａａｒ調節薬としてのピラゾールカルボキサミド誘導体 | |
| WO2011058478A1 (en) | Substituted triazolopyrimidines as pde8 inhibitors | |
| US20130150376A1 (en) | Novel Sultam Compounds | |
| HK1171220B (en) | Imidazole derivatives as casein kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20170716 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20170716 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |